Takeda announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial
Takeda announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial
HUTCHMED (HCM) announces that its partner Takeda (TAK) received notification that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of fruquintinib
Takeda (TAK), Astellas Pharma (ALPMY), and Sumitomo Mitsui (SMFG) announced that the three companies signed a master agreement on April 22 to establish a joint venture company. The new company
Takeda “announced that the FDA has approved ENTYVIO subcutaneous administration for maintenance therapy in adults with moderately to severely active Crohn’s disease after induction therapy with intravenous ENTYVIO. The subcutaneous
Takeda בחרו שמונה קבוצות לא רווחיות חדשות בארה”ב לקבלת מענקים. זה חלק מההבטחה שלהם לתת 14.6 מיליון דולר במהלך שנת הכספים 2023 שלהם כדי לעזור לחברה באמריקה. Takeda שואפים לעשות